Publisher
Springer International Publishing
Reference21 articles.
1. Haberlandt E. Ludwig Haberlandt--A pioneer in hormonal contraception. Wien Klin Wochenschr. 2009;121(23-24):746–9.
2. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol. 1993;100(9):832–8.
3. Burkman R, et al. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception. 2011;84:19–34.
4. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–74.
5. Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;4:CD003552.